Literature DB >> 7256475

Multiple sclerosis and neuromyelitis optica. Case report and speculation.

J E Cosnett.   

Abstract

Among the indigenous people of tropical and subtropical countries neuromyelitis optica is more common than multiple sclerosis (MS), which is exceptionally rare. Alternatively, one might conclude that when MS does occur in these countries it usually assumes the spinal-optic form. The evidence on which these statements are based is reviewed, and 6 cases from Natal are presented. These observations could have a bearing on the pathogenesis and epidemiology of MS.

Entities:  

Mesh:

Year:  1981        PMID: 7256475

Source DB:  PubMed          Journal:  S Afr Med J


  5 in total

1.  Demyelinating disorder of the central nervous system occurring in black South Africans.

Authors:  G Modi; A Mochan; M Modi; D Saffer
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-04       Impact factor: 10.154

2.  Multiple sclerosis in black South Africans and Zimbabweans.

Authors:  G Dean; A I Bhigjee; P L Bill; V Fritz; I C Chikanza; J E Thomas; L F Levy; D Saffer
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-09       Impact factor: 10.154

3.  Challenges in the diagnosis and treatment of CNS demyelinating disorders in Zambia.

Authors:  Dhanashri P Miskin; Altaf Saadi; Laston Chikoya; Jacob A Sloane; Igor J Koralnik; Omar K Siddiqi
Journal:  Mult Scler J Exp Transl Clin       Date:  2016-07-04

4.  The neuromyelitis optica presentation and the aquaporin-4 antibody in HIV-seropositive and seronegative patients in KwaZulu-Natal, South Africa.

Authors:  Ahmed I Bhigjee; Anandan A Moodley; Izanne Roos; Cait-Lynn Wells; Pratistadevi Ramdial; Monika Esser
Journal:  South Afr J HIV Med       Date:  2017-01-31       Impact factor: 2.744

5.  Effect of Obesity on Retinal Integrity in African Americans and Caucasian Americans With Relapsing Multiple Sclerosis.

Authors:  Jacob Rube; Madeline Bross; Christopher Bernitsas; Melody Hackett; Fen Bao; Evanthia Bernitsas
Journal:  Front Neurol       Date:  2021-11-24       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.